Related references
Note: Only part of the references are listed.Prevention of osteoporosis-related fractures among postmenopausal women and older men
Poupak Rahmani et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2009)
Bisphosphonate-associated adverse events
Peter D. Papapetrou
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM (2009)
Bisphosphonates in the management of postmenopausal osteoporosis - optimizing efficacy in clinical practice
Oliver Bock et al.
CLINICAL INTERVENTIONS IN AGING (2008)
Effects of continuing or stopping alendronate after 5 years of treatment - The Fracture Intervention Trial long-term extension (FLEX): A randomized trial
Dennis M. Black et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2006)
Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
JY Reginster et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
Jean-Yves Reginster et al.
CLINICAL INTERVENTIONS IN AGING (2006)
Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study
PD Miller et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE
CH Chesnut et al.
CURRENT MEDICAL RESEARCH AND OPINION (2005)
Ten years' experience with alendronate for osteoporosis in postmenopausal women
HG Bone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis
CH Chesnut et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2004)
Seven years of treatment with risedronate in women with postmenopausal osteoporosis
DD Mellström et al.
CALCIFIED TISSUE INTERNATIONAL (2004)
Alendronate in the prevention of osteoporosis: 7-year follow-up
PN Sambrook et al.
OSTEOPOROSIS INTERNATIONAL (2004)
Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience
OH Sorensen et al.
BONE (2003)
Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents
MC Hochberg et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
The influence of osteoporotic fractures on health-related quality of life in community-dwelling men and women across Canada
JD Adachi et al.
OSTEOPOROSIS INTERNATIONAL (2001)
Antifracture efficacy of antiresorptive agents are related to changes in bone density
RD Wasnich et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
JY Reginster et al.
OSTEOPOROSIS INTERNATIONAL (2000)
Share Paper
